Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemolizumab in Chinese Subjects With Moderate-to-Severe Atopic Dermatitis
NCT07762833Phase 3Recruiting
- Sponsor
- Galderma
- Start
- Oct 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
A Phase 3 trial of nemolizumab in atopic dermatitis (AD), sponsored by Galderma. Started Oct 2026; status: recruiting.
02
Drugs
nemolizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07762833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07762833.